drugset / Trial / NCT04277936

Pharmacologic Modulation of Hippocampal Activity in Psychosis

NCT04277936

Phase 2 Terminated 1 enrolled Vanderbilt University Medical Center
NaSingle-groupOpen-labelBasic science

Summary

The purpose of this study is to test whether administration of levetiracetam (LEV), a commonly used anti-epileptic that alters neurotransmitter release, can reduce hippocampal hyperactivity. Specifically, we will utilize two functional magnetic resonance imaging (MRI) techniques: 1) blood oxygen level dependence (BOLD) contrast will assess activity with a visual scene processing task that engages the anterior hippocampus and 2) arterial spin labeling (ASL) will assess baseline activity. This study will also assess whether patients have improvement in their symptoms after receiving LEV. Previous studies in people with psychotic disorders have shown that the hippocampus is hyperactive and more activity correlates with worsening of clinical symptoms. Therefore, the aim of this study is to use an intervention to further understand the underlying mechanisms of the hippocampus in psychosis.

Timeline

Start
2020-05-11
Primary completion
2020-08-31
Completion
2020-08-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Levetiracetam Other / unclassified 250 mg Oral

Indications